BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35362880)

  • 1. Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer's Disease.
    Do KV; Hjorth E; Wang Y; Jun B; Kautzmann MI; Ohshima M; Eriksdotter M; Schultzberg M; Bazan NG
    Cell Mol Neurobiol; 2023 Mar; 43(2):797-811. PubMed ID: 35362880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid neutral lipids predict progression from mild cognitive impairment to Alzheimer's disease.
    Dakterzada F; Jové M; Huerto R; Carnes A; Sol J; Pamplona R; Piñol-Ripoll G
    Geroscience; 2024 Feb; 46(1):683-696. PubMed ID: 37999901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal Fluid Inflammatory Markers in Alzheimer's Disease: Influence of Comorbidities.
    Wang Y; Emre C; Gyllenhammar-Schill H; Fjellman K; Eyjolfsdottir H; Eriksdotter M; Schultzberg M; Hjorth E
    Curr Alzheimer Res; 2021; 18(2):157-170. PubMed ID: 33784960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition.
    Cullen NC; Mälarstig AN; Stomrud E; Hansson O; Mattsson-Carlgren N
    Sci Rep; 2021 Jan; 11(1):1965. PubMed ID: 33479445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease.
    Mouton-Liger F; Dumurgier J; Cognat E; Hourregue C; Zetterberg H; Vanderstichele H; Vanmechelen E; Bouaziz-Amar E; Blennow K; Hugon J; Paquet C
    Alzheimers Res Ther; 2020 Jul; 12(1):88. PubMed ID: 32690068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease.
    Sarlus H; Eyjolfsdottir H; Eriksdotter M; Oprica M; Schultzberg M
    J Alzheimers Dis; 2015; 48(2):495-505. PubMed ID: 26402013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal delivery of pro-resolving lipid mediators rescues memory and gamma oscillation impairment in App
    Emre C; Arroyo-García LE; Do KV; Jun B; Ohshima M; Alcalde SG; Cothern ML; Maioli S; Nilsson P; Hjorth E; Fisahn A; Bazan NG; Schultzberg M
    Commun Biol; 2022 Mar; 5(1):245. PubMed ID: 35314851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's Disease and Specialized Pro-Resolving Lipid Mediators: Do MaR1, RvD1, and NPD1 Show Promise for Prevention and Treatment?
    Miyazawa K; Fukunaga H; Tatewaki Y; Takano Y; Yamamoto S; Mutoh T; Taki Y
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.
    Babić Leko M; Borovečki F; Dejanović N; Hof PR; Šimić G
    J Alzheimers Dis; 2016; 50(3):765-78. PubMed ID: 26836160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
    Oikonomidi A; Tautvydaitė D; Gholamrezaee MM; Henry H; Bacher M; Popp J
    J Alzheimers Dis; 2017; 60(1):273-281. PubMed ID: 28826184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis.
    Zhu M; Wang X; Hjorth E; Colas RA; Schroeder L; Granholm AC; Serhan CN; Schultzberg M
    Mol Neurobiol; 2016 May; 53(4):2733-49. PubMed ID: 26650044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease.
    Lim B; Tsolaki M; Soosaipillai A; Brown M; Zilakaki M; Tagaraki F; Fotiou D; Koutsouraki E; Grosi E; Prassas I; Diamandis EP
    Clin Chem Lab Med; 2019 Nov; 57(12):1875-1881. PubMed ID: 31415236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.
    Bartels C; Kögel A; Schweda M; Wiltfang J; Pentzek M; Schicktanz S; Schneider A
    J Alzheimers Dis; 2020; 78(3):1137-1148. PubMed ID: 33104034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.